Keros Triggers $20M Milestone from Takeda as Elritercept Phase 3 Begins; Plans 25% Payout to Shareholders

summarizeSummary

Keros Therapeutics earned a $20 million milestone payment from Takeda after dosing the first patient in the Phase 3 ELRiSE MDS trial of elritercept. The company plans to distribute 25% of the net proceeds to shareholders.

check_boxKey Events · Product Development and Regulatory · KROS

• Phase 3 Trial Start Triggers $20M Milestone

  Dosing of the first patient in the ELRiSE MDS Phase 3 trial of elritercept triggered a $20 million development milestone payment from partner Takeda under the January 2025 license agreement.

• 25% of Net Proceeds to Be Distributed to Stockholders

  Keros expects to distribute 25% of the net cash proceeds from the milestone payment to stockholders following receipt, an unusual direct return of capital alongside clinical progress.

• Non-Dilutive Cash Strengthens Balance Sheet

  The $20 million milestone adds to the $281 million cash position reported as of Q1 2026, providing additional runway without dilution.

• Elritercept Program Advances Toward Registration

  The Phase 3 ELRiSE MDS trial compares elritercept to epoetin alfa in anemia due to low-risk MDS, building on positive Phase 2 signals and moving the program closer to potential approval.

auto_awesomeAnalysis · KROS · Life Sciences

Dosing the first patient in the Phase 3 ELRiSE MDS trial unlocks a $20 million development milestone from partner Takeda under the 2025 license agreement. Keros intends to distribute 25% of the net proceeds directly to stockholders — an unusual move that returns capital while the pivotal trial advances. The milestone adds non-dilutive cash to a balance sheet that held $281 million as of Q1 2026, and the Phase 3 start de-risks the elritercept program, which already generated a $200 million upfront payment.